问题

The study addresses the increasing competition in the pharmaceutical industry and the importance of profitability for sustainable development. It aims to evaluate Yunnan Baiyao Group Co., Ltd.'s profitability to identify management deficiencies and promote rapid enterprise development.

方法

The research employs an improved DuPont analysis system, incorporating cash flow indicators, to assess the profitability of Yunnan Baiyao Group Co., Ltd. The analysis covers the period from 2020 to 2023, examining various financial ratios and performance metrics.

关键发现

The analysis reveals challenges in cost control, a slowdown in main business growth, and a decline in accounts receivable turnover. Despite these issues, Yunnan Baiyao maintains a relatively stable profit composition, although its gross profit margin is lower than the industry average.

3个要点

• Yunnan Baiyao faces increasing cost pressures, impacting its gross profit margin and overall profitability.
• The company's main business growth is weakening, affecting its cash sales ratio and market competitiveness.
• Inefficient accounts receivable management contributes to a declining turnover rate, necessitating improved credit policies.